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Perceptions that influence ADF prescribing
Methods
Electronic survey sent via medical licensure board to all DEA 
prescriber registrants in Kentucky, Oct/Nov 2019. Response 
proportion (8.5%) was similar to other unincentivized health 
care provider surveys (N=480 eligible). Some analyses limited 
to prescribers who prescribe controlled substances.
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Perceptions that influence ADF prescribing
ADF properties are not top of mind when considering 
which opioid to prescribe. This phenomena may limit the 
extent of patient selection bias with reformulated 
OxyContin. But it may also




ADF dispensing shows pockets 
of concentration. Areas with 
high rates of opioid prescribing 
and overdose do not necessarily 
have greater ADF penetration.
ADF dispensing varies by location
Brown JR, Oh GY, et al. 2020 – Journal of Rural Health. 10.1111/jrh.12496
Methods
Analysis of Prescription Monitoring Program data from CA, FL, KY 
for outpatient opioid prescriptions dispensed to adult residents in 
2018. ADFs included: OxyContin, Hysingla ER, MorphaBond, 
Embeda, and Xtampza ER. 
Annual rate of ADF dispensing per 1,000 Adult Opioid Patients











The [NOMAD] study leads us to consider 
whether abuse deterrence is an inherent 
property of the drug itself, or if its intended 
effect lies in an interaction with social context. 
If we accept that abuse deterrence in the 
community is more than a biochemical 
property, label language becomes becomes all 
the more challenging, albeit with the potential 
to be more scientifically accurate. 
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